The efficacy of SGLT2 inhibitor switching from thiazolidine about body weight and metabolic-related factors in type 2 diabetes patients
Phase 4
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000022804
- Lead Sponsor
- Hokkaido Unverstiy Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1) Already taking SGLT2 inhibitor agents 2) With hypersensitivity to Dapagliflozin 3) With severe or unstable retinopathy 4) With severe liver or kidney disfunction 5) With severe diabetic ketosis, pre-coma, or coma 6) With severe infection or trauma, or in perioperation 7) With pregnancy 8) Patients who thought to be inappropriate to enter this study for some reasons by physician's judgments
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Body weight and HbA1c at 24 weeks
- Secondary Outcome Measures
Name Time Method Abdominal circumference Blood pressure Lipid metabolism Liver function Complete blood count, renal function, electrolyte Urine test Frequency of hypoglycemia Dose of antidiabetic drugs before and during clinical trial